Eric Liu
YOU?
Author Swipe
View article: Post-viral Immune-Mediated Vasculitis Following Concurrent Dengue and Chikungunya Infection: A Case Report
Post-viral Immune-Mediated Vasculitis Following Concurrent Dengue and Chikungunya Infection: A Case Report Open
We present a case of a 78-year-old female who developed persistent neurological complications following a concurrent dengue and chikungunya viral infection. The patient experienced progressive weakness and ambulatory difficulties, culminat…
View article: Molecular Axis Distribution Moments in Ultrafast Transient Absorption Spectroscopy: A Path Towards Ultrafast Quantum State Tomography
Molecular Axis Distribution Moments in Ultrafast Transient Absorption Spectroscopy: A Path Towards Ultrafast Quantum State Tomography Open
In ultrafast experiments with gas phase molecules, the alignment of the molecular axis relative to the polarization of the interacting laser pulses plays a crucial role in determining the dynamics following this light-matter interaction. T…
View article: A case report: Treating insomnia with olanzapine in cancer patients
A case report: Treating insomnia with olanzapine in cancer patients Open
Objectives Patients with cancer frequently experience insomnia that significantly impacts their quality of life, worsens existing symptoms, and potentially hinders treatment outcomes and recovery. Here, we report on 3 cancer patients whose…
View article: Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma Open
Background: North American ATLL (NA-ATLL) is a highly aggressive HTLV-I-associated T-cell malignancy with a dismal prognosis. Venetoclax has shown activity in other T-cell malignancies, alone or in combination with hypomethylating agents (…
View article: North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist
North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist Open
Background: Adult T-cell leukemia/lymphoma (ATLL) is a fatal cancer caused by the human T-lymphotropic virus-1 (HTLV-1) and somatic mutations in virus-infected CD4 T cells. With limited treatment options, patients with ATLL urgently need n…
View article: ANVIL: Anomaly-based Vulnerability Identification without Labelled Training Data
ANVIL: Anomaly-based Vulnerability Identification without Labelled Training Data Open
Supervised-learning-based vulnerability detectors often fall short due to limited labelled training data. In contrast, Large Language Models (LLMs) like GPT-4 are trained on vast unlabelled code corpora, yet perform only marginally better …
View article: Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients
View article: Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, …
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences
View article: Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, …
View article: Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from …
View article: Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was qua…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from …
View article: Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was qua…
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by con…
View article: Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by con…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences